Non-Invasive Prenatal Testing
Clarix™
Clarix™ is Ingenes' non-invasive prenatal test. It analyzes the baby's 23 chromosome pairs from week 10 with 99% certainty, using a simple maternal blood sample. No miscarriage risk, no amniocentesis.
Clarix™ is the non-invasive prenatal genetic test developed at Ingenes that analyzes your baby's chromosomal health from week 10 of pregnancy, using a simple maternal blood sample. No amniocentesis, no chorionic villus sampling, no miscarriage risk.
The test works because during pregnancy, free fetal DNA circulates in the mother's blood. Clarix™ isolates that DNA and analyzes it with massive parallel sequencing (NGS-Pair end) technology to detect alterations across all 23 of the baby's chromosome pairs.
The result: 99% certainty to identify syndromes such as Down, Edwards, Patau or Turner, plus the baby's sex from week 10 (6 weeks earlier than ultrasound can confirm). Key information to make informed decisions with genetic backing, without putting the pregnancy at risk.
- Week 0 From the first trimester
- 0% Diagnostic certainty
- Zero Miscarriage risk
Why choose Clarix™ over other prenatal tests
-
Non-invasive, no risk
Only a maternal blood sample is needed. Unlike amniocentesis or chorionic villus sampling, it does not cross the placenta or the amniotic sac. Zero miscarriage risk.
-
Covers all 23 chromosome pairs
Many similar tests only cover the most common chromosomes. Clarix™ analyzes the full 23 pairs, detecting less frequent aneuploidies that other tests miss.
-
Maternal-Fetal backing at the same site
If the result is abnormal, at Ingenes we send you straight to our Maternal-Fetal Unit and clinical geneticists. No time lost bouncing between outside specialists.
Fetal DNA in maternal blood: the basis of the test
During pregnancy, fragments of the baby's DNA circulate freely in the mother's blood. They come from the placenta and can be detected from week 10 of gestation, when they reach a concentration high enough for reliable analysis.
Clarix™ isolates that fetal DNA from a maternal blood sample (one tube, no needle in the abdomen, no uterine instrumentation) and processes it with massive parallel sequencing (NGS-Pair end), one of the most precise genetic technologies available today.
The analysis covers all 23 chromosome pairs and detects both classic aneuploidies (trisomies 21, 18, 13) and sex chromosome alterations (Turner, Klinefelter, Triple X). It also identifies the baby's sex with high precision from week 10, much earlier than ultrasound (which only confirms it around week 16).
Your path is unique. So is your plan.
We design a protocol tailored to you after understanding your story and your previous tests. No generic diagnoses or protocols.
Profiles where Clarix™ adds clinical value
-
Advanced maternal age
Women over 35, where the risk of chromosomal aneuploidies rises. Above 40, the probability increases significantly.
-
Assisted reproduction pregnancies without PGT-A
If you reached pregnancy via IVF without prior embryo genetic study (PGT-A), Clarix™ provides the baby's chromosomal information directly from maternal blood.
-
Family history of chromosomal alterations
Families with history of Down, Edwards or any aneuploidy. Clarix™ detects those same conditions before the second trimester.
-
Abnormal result in first-trimester screening
If ultrasound or biochemical screening showed elevated risk, Clarix™ is the non-invasive alternative to diagnosis before considering amniocentesis.
-
Want to know the baby's sex from week 10
No need to wait for the morphological ultrasound at weeks 16-20. Clarix™ confirms sex with high precision 6 weeks earlier.
-
Twin pregnancy
With the Clarix™ Gemelar Plus modality, the analysis covers twin pregnancies, where traditional screening loses precision.
Four steps, one single blood sample
1. Maternal blood sample. At any of our branches, a tube of blood is drawn from your arm. No special fasting, no prior preparation, no contraindications for pregnancy. Takes less than 5 minutes.
2. Free fetal DNA isolation. In our Molecular Biology Lab, fetal DNA is separated from maternal DNA. Validated techniques allow working with the small fraction of the baby's DNA circulating freely in your plasma.
3. Massive parallel sequencing (NGS-Pair end). Millions of DNA fragments are analyzed in parallel with one of the most precise genetic technologies available. The processing is bioinformatic and compares the baby's chromosomal pattern with the expected one.
4. Clinical report and referral if needed. In approximately 10 days you have the result. If normal, we deliver it along with the baby's sex information. If there is an alteration, we schedule directly with our Maternal-Fetal Unit and a clinical geneticist to walk you through the next steps.
Chromosomal alterations Clarix™ identifies
-
Down Syndrome (Trisomy 21)
Extra chromosome 21. The best-known trisomy and the classic indication for prenatal screening in advanced maternal age.
-
Edwards Syndrome (Trisomy 18)
Extra chromosome 18. Causes severe multiple malformations and, in most cases, early pregnancy loss or neonatal death.
-
Patau Syndrome (Trisomy 13)
Extra chromosome 13. Like Edwards, usually incompatible with life or accompanied by severe neurological involvement.
-
Turner Syndrome (X0)
Missing X chromosome in female babies. Associated with short stature, cardiac issues and ovarian dysgenesis. Clarix™ detects it before the first trimester ends.
-
Klinefelter Syndrome (XXY)
Extra X chromosome in male babies. Affects testicular development and fertility. Frequently underdiagnosed without prenatal screening.
-
Triple X, Jacobs and other aneuploidies
Triple X (XXX), Jacobs (XYY) and other alterations across the 23 pairs. The analysis covers all chromosomes, not just the most common ones.
Clarix™ Plus and Clarix™ Gemelar Plus
Clarix™ Plus is the expanded version of the test for single pregnancies. It covers all 23 chromosome pairs and adds microdeletion analysis (small losses of genetic material that can cause serious syndromes such as DiGeorge, Cri-du-chat or Prader-Willi).
Clarix™ Gemelar Plus is specifically designed for twin pregnancies, where traditional prenatal screening loses a lot of precision. It analyzes the free fetal DNA from both babies and reports the joint result. Especially useful in spontaneous and IVF twin pregnancies.
Both modalities are processed with the same NGS-Pair end technology. Your physician recommends the appropriate option based on your case, gestational age and history. At the consultation we explain which applies and why.
Clarix™ within the TripleMed™ model
Clarix™ is not just a test sent to an external lab and delivered by email. At Ingenes it is integrated into the TripleMed™ model, which combines reproductive medicine, genetic and regenerative medicine, and maternal-fetal medicine in a single follow-up plan.
That means if the result is normal, we deliver it along with guidance on the next pregnancy steps. And if it is abnormal, the day the result arrives there is already a consultation scheduled with our Maternal-Fetal Unit and a clinical geneticist from the team. No waiting for referrals or losing critical time.
We work with our own Molecular Biology lab and academic alliance with Cinvestav-IPN, one of the most important genetic research centers in Mexico. That collaboration is what allows us to offer Clarix™ with validated NGS technology and reports with immediate clinical backing.
Frequently asked questions about Clarix™
Is it really non-invasive? Is there a miscarriage risk?
Yes, totally non-invasive. Only a blood sample from the mother's arm is taken. Neither the placenta nor the amniotic sac is crossed, so the pregnancy loss risk is zero. Amniocentesis, in contrast, has approximately 0.5 to 1% miscarriage risk.
From what week can it be done?
From week 10 of pregnancy. Before that week, the amount of free fetal DNA in maternal blood is not enough for reliable analysis. There is no strict upper limit: it can be done at any point in pregnancy if not done earlier.
What is the difference between Clarix™, Clarix™ Plus and Clarix™ Gemelar Plus?
Clarix™ analyzes the 23 chromosome pairs. Clarix™ Plus adds microdeletion analysis (small losses of genetic material that cause specific syndromes). Clarix™ Gemelar Plus is designed for twin pregnancies, where traditional screening loses precision. Your physician recommends the modality based on your case.
How long does the result take?
Approximately 10 days from sample collection. If there is an alteration, we call you to schedule a consultation with the Maternal-Fetal Unit and a clinical geneticist before delivering the written report, so you receive the information with proper support.
Does it detect all possible genetic diseases?
No. Clarix™ detects chromosomal aneuploidies (alterations in chromosome number) and, in the Plus version, specific microdeletions. It does not detect monogenic diseases like cystic fibrosis or muscular dystrophy (for that there is PGT-M, done before embryo transfer), nor structural malformations (for that there are morphological ultrasounds).
If the result is abnormal, what happens?
A direct consultation is scheduled with our Maternal-Fetal Unit and a clinical geneticist from the Ingenes team. We explain what the result means, the diagnostic confirmation options (amniocentesis if applicable) and pregnancy follow-up. The information always arrives with proper support, not just by email.
Do I need to be an Ingenes patient to get Clarix™?
No. If your pregnancy is spontaneous or followed by another physician, you can get Clarix™ at Ingenes and deliver the result to your trusted Maternal-Fetal specialist. Also applies to patients who reached pregnancy via IVF at another clinic.
How much does Clarix™ cost?
The cost varies by modality (Clarix™, Plus or Gemelar Plus). We discuss it in detail when scheduling the test, with concrete numbers based on your case.
Are you more than 10 weeks pregnant?
Clarix™ is done with a simple maternal blood sample. Zero miscarriage risk, results in approximately 10 days. If you are already in follow-up with your Maternal-Fetal specialist, you can take the results straight to them.
Contact us